COPD Medication | INCRUSE® ELLIPTA® (umeclidinium)
Once-daily INCRUSE is a prescription medicine used long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing and fewer flare-ups.
Actived: Sunday Jan 17, 2021
Frequently Asked Questions | INCRUSE ELLIPTA (umeclidinium)
COPD is a condition that makes it hard to breathe, and worsens over time. COPD includes chronic bronchitis, emphysema, or both. Chronic bronchitis is increased cough and mucus production caused by inflammation of the airways. Bronchitis is considered chronic (or long term) if a person coughs and produces excess mucus most days for several months during 2 years in a row.
About INCRUSE ELLIPTA (umeclidinium)
INCRUSE ELLIPTA helps people with COPD breathe better for a full 24 hours. Your results may vary. INCRUSE ELLIPTA is not for use to treat sudden symptoms of COPD. Always have a rescue inhaler (an inhaled, short-acting bronchodilator) with you to treat sudden symptoms.
Risks & Side Effects of INCRUSE ELLIPTA (umeclidinium)
RISKS & SIDE EFFECTS. Please review this safety information. Below you can learn about risks and side effects of INCRUSE. This, however, is not all the safety information for INCRUSE and does not replace talking to your healthcare professional about your medical condition or treatment.